You only live twice: long-term results with the Lentis MAX

Session Details

Session Title: New IOLs: Material & Preload IOL

Session Date/Time: Monday 24/09/2018 | 08:00-10:30

Paper Time: 08:00

Venue: Room A3, Podium 2

First Author: : A.Borkenstein AUSTRIA

Co Author(s): :    E. Borkenstein                    

Abstract Details

Purpose:

To evaluate long term results after implanting a magnifying high add IOL in eyes with cataract and progressed ARMD. To identify if implanting such a high add IOL (Lentis MAX LS-313 MF80, Oculentis, Germany) enhances quality of life and individual independence in daily routine. To analyze clinical results > one year after surgery.

Setting:

Borkenstein & Borkenstein, private practice at the Privatklinik der Kreuzschwestern Graz, Austria.

Methods:

In this case series 11 subjects with clinical significant cataract and progressed dry ARMD with BCDVA of 1.3 -0.5 logMAR were included. In all cases the aspheric, biconvex, sector shaped foldable one-piece IOL (Lentis MAX LS-313 MF80, Oculentis Germany) with an IOL add power of 8.0 dpt. (= 6.0 dpt. spectacle plane) was implanted. OCT control exams were performed every 4-6 weeks.

Results:

In our long term observation (> 1 year) attention was turned to the effect of training and neuroadaption. Results were divided into objective (BCNVA, BCDVA, OCT) and subjective measured (quality of life, independence, autonomy in daily routine). The BCDVA improved in all cases immediately after surgery, UCNVA improved but required more time. Every day training was important to achieve further improvement. No halos or glare were reported and OCT measurements showed stable diagnostic findings. After one year all individuals ranked their quality of life higher than before.

Conclusions:

We can report a very high patient satisfaction. Our subjective and objective measured results showed that improvement can be achieved with training after 6-12 months postoperatively. Implanting a high add IOL is a promising alternative in low-vision patients with late ARMD and cataracts. These patients need some special attention and support in the postoperative period.

Financial Disclosure:

None

Financial Disclosure:

-